Corrigendum to ‘‘An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension' [Regul. Toxicol. Pharmacol. 2012, 95–103]

Subjects

Subjects :

medicine.medical_specialty
business.industry
Endothelin receptor antagonist
General Medicine
Pharmacology
Toxicology
Endocrinology
Internal medicine
Sitaxentan
medicine
business
Carcinogen
medicine.drug
Preclinical toxicity

Details

ISSN :

02732300

Volume :

64

Database :

OpenAIRE

Journal :

Regulatory Toxicology and Pharmacology

Accession number :

edsair.doi...........3e5716e0e98d15e88f9c71e4fd96afcd

Full Text :

https://doi.org/10.1016/j.yrtph.2012.07.012